Aptevo enters ATM equity facility up to $2.96M; reports preliminary Q1 cash of $2.1M

Aptevo Therapeutics Inc.

Entered ATM sales agreement with Roth Capital to sell up to $2,959,952 in common stock; Roth receives 3.0% commission.
Preliminary cash and equivalents as of March 31, 2025: $2.1M (unaudited, subject to change).
Subsequent registered direct offerings on April 4 and April 22 raised approx. $1.9M and $1.8M respectively.
Company has not finalized Q1 2025 financial results; independent auditor has not reviewed preliminary data.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.